PolyNovo hits $150M annual group revenue

• PolyNovo reported unaudited group revenue of $150 million for FY26, representing a 16.1% increase over FY25.
• Following the announcement, the PolyNovo share price was down at $0.90.
• Growth was driven by an 89.6% expansion in NovoSorb MTX sales and strong performance in North America.

Medical technology company PolyNovo (ASX:PNV) reported a 16.1% rise in annual group revenue to $150 million for FY26.

The outcome compares to group revenue of $129.2 million generated during the previous financial year.

"We're pleased to have finished the financial year strongly, with record sales recorded in the U.S. in June," said PolyNovo CEO Bruce Peatey.

Operating cash flow grew to $3.5 million in progress receipts from insurance claims.

PolyNovo stated it expects additional insurance payments during FY27, following the announcement the PolyNovo share price was down at $0.90.

The business completed construction of its main manufacturing facility, with final machinery payments of $1.5 million due in FY27.

Commercial sales of the NovoSorb MTX product line expanded by 89.6% to reach $12.6 million for the year.